Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Female, ≥ 18 years.~* Histologically confirmed invasive breast cancer.~* Metastatic breast cancer.~* Karnofsky Performance Status ≥60.~* Life expectancy of more than 3 months.~* Subject must have adequate organ function.~* Normal laboratory values: hemoglobin \> 80g/dl, neutrophils \> 2.0×10\^9/L, platelets \> 80×10\^9/L, serum creatinine \< upper limit of normal (ULN), serum bilirubin \< ULN, ALT and AST \< 2.5×ULN, AKP \< 5×ULN.~* Negative serum pregnancy test for women with childbearing potential.~* Good conditions for infusion and willing to have phlebotomy throughout whole study.~* Have ceased anti-tumor treatments including endocrinotherapy and bio-targeted therapy for more than 28 days.~* Have at least one target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~* No prior use of docetaxel or has used docetaxel in adjuvant/neo-adjuvant chemotherapy and has a relapse free survival of at least 12 months.~Exclusion Criteria:~* Pregnant or lactating females.~* History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety.~* Active or uncontrolled infection.~* Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.~* Concomitant with brain metastases.~* Have received chemotherapy after metastasis.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- arm A (Type: ACTIVE_COMPARATOR): docetaxel and cisplatin chemotherapy
- arm B (Type: EXPERIMENTAL): docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
- arm C (Type: EXPERIMENTAL): docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).